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Introduction
Ventilator-associated pneumonia (VAP) is deﬁ ned as 
pneumonia that occurs 48–72 hours or thereafter follow-
ing endotracheal intubation, characterized by the pre-
sence of a new or progressive inﬁ ltrate, signs of systemic 
infection (fever, altered white blood cell count), changes 
in sputum characteristics, and detection of a causative 
agent [1]. VAP contributes to approximately half of all 
cases of hospital-acquired pneumonia [1], [2]. VAP is 
estimated to occur in 9–27  % of all mechanically 
ventilated patients, with the highest risk being early in 
the course of hospitalization [1], [3]. It is the second most 
common nosocomial infection in the intensive care unit 
(ICU) and the most common in mechanically ventilated 
patients [4], [5]. VAP rates range from 1.2 to 8.5 per 1,000 
ventilator days and are reliant on the deﬁ nition used for 
diagnosis [6]. Risk for VAP is greatest during the ﬁ rst 
5  days of mechanical ventilation (3  %) with the mean 
duration between intubation and development of VAP 
being 3.3  days [1], [7]. Th is risk declines to 2  %/day 
between days 5 to 10 of ventilation, and 1  %/day 
thereafter [1], [8]. Earlier studies placed the attributable 
mortality for VAP at between 33–50  %, but this rate is 
variable and relies heavily on the underlying medical 
illness [1]. Over the years, the attributable risk of death 
has decreased and is more recently estimated at 9–13 % 
[9], [10], largely because of implementation of preventive 
strategies. Approximately 50 % of all antibiotics adminis-
tered in ICUs are for treatment of VAP [2], [4]. Early 
onset VAP is deﬁ ned as pneumonia that occurs within 
4 days and this is usually attributed to antibiotic sensitive 
pathogens whereas late onset VAP is more likely caused 
by multidrug resistant (MDR) bacteria and emerges after 
4 days of intubation [1], [4]. Th us, VAP poses grave 
implications in endotracheally intubated adult patients in 
ICUs worldwide and leads to increased adverse outcomes 
and healthcare costs. Independent risk factors for 
develop ment of VAP are male sex, admission for trauma 
and intermediate underlying disease severity, with odds 
ratios (OR) of 1.58, 1.75 and 1.47–1.70, respectively [7].
Pathogenesis
Th e complex interplay between the endotracheal tube, 
presence of risk factors, virulence of the invading bacteria 
and host immunity largely determine the development of 
VAP. Th e presence of an endotracheal tube is by far the 
most important risk factor, resulting in a violation of 
natural defense mechanisms (the cough reﬂ ex of glottis 
and larynx) against microaspiration around the cuﬀ  of 
the tube [4], [11]. Infectious bacteria obtain direct access 
to the lower respiratory tract via: (1)  microaspiration, 
which can occur during intubation itself; (2) development 
of a bioﬁ lm laden with bacteria (typically Gram-negative 
bacteria and fungal species) within the endotracheal 
tube; (3)  pooling and trickling of secretions around the 
cuﬀ ; and (4)  impairment of mucociliary clearance of 
secretions with gravity dependence of mucus ﬂ ow within 
the airways [11]–[13]. Pathogenic material can also 
collect in surrounding anatomic structures, such as the 
stomach, sinuses, nasopharynx and oropharynx, with 
replacement of normal ﬂ ora by more virulent strains [11], 
[12], [14]. Th is bacterium-enriched material is also 
constantly thrust forward by the positive pressure exerted 
by the ventilator. Whereas reintubation following extu-
bation increases VAP rates, the use of non-invasive 
positive pressure ventilation has been associated with 
signiﬁ cantly lower VAP rates [4]. Host factors such as the 
severity of underlying disease, previous surgery and 
antibiotic exposure have all been implicated as risk 
factors for development of VAP [1].
In addition, it has recently been noted that critically ill 
patients may have impaired phagocytosis and behave as 
functionally immunosuppressed even prior to emergence 
of nosocomial infection [4], [15], [16]. Th is eﬀ ect is 
attributed to the detrimental actions of the anaphylatoxin, 
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C5a, which impairs neutrophil phagocytic activity and 
impairs phagocytosis by neutrophils [15]. More recently, 
a combined dysfunction of T-cells, monocytes, and neu-
tro phils has been noted to predict acquisition of noso-
comial infection [16]. For example, elevation of regula-
tory T-cells (Tregs), monocyte deactivation (measured by 
monocyte HLA-DR expression) and neutrophil dysfunc-
tion (measured by CD88 expression), have cumulatively 
shown promise in predicting infection in the critically ill 
population, as compared to healthy controls [16].
Microbiology
Th e type of organism that causes VAP usually depends on 
the duration of mechanical ventilation. In general, early 
VAP is caused by pathogens that are sensitive to anti-
biotics, whereas late onset VAP is caused by multi-drug 
resistant and more diﬃ  cult to treat bacteria. However, 
this is by no means a rule and merely a guide to initiate 
antibiotic therapy until further clinical infor mation is 
available.
Typically, bacteria causing early-onset VAP include 
Streptococcus pneumoniae (as well as other streptococcus 
species), Hemophilus inﬂ uenzae, methicillin-sensitive 
Staphylo coccus aureus (MSSA), antibiotic-sensitive 
enteric Gram-negative bacilli, Escherichia coli, Klebsiella 
pneumonia, Enterobacter species, Proteus species and 
Serratia marcescens. Culprits of late VAP are typically 
MDR bacteria, such as methicillin-resistant S. aureus 
(MRSA), Acinetobacter, Pseudomonas aeruginosa, and 
extended-spectrum beta-lactamase producing bacteria 
(ESBL) [4]. Th e exact prevalence of MDR organisms is 
variable between institutions and also within institutions 
[1]. Patients with a history of hospital admission for 
≥  2  days in the past 90  days, nursing home residents, 
patients receiving chemotherapy or antibiotics in the last 
30  days and patients undergoing hemodialysis at out-
patient centers are susceptible to drug resistant bacteria 
[1], [4]. Commonly found bacteria in the oropharynx can 
attain clinically signiﬁ cant numbers in the lower airways. 
Th ese bacteria include Streptococcus viridans, Coryne-
bacterium, coagulase-negative staphylococcus (CNS) and 
Neisseria species. Frequently, VAP is due to polymicrobial 
infection. VAP from fungal and viral causes has a very 
low incidence, especially in the immunocompetent host 
[1].
Pathogens causing VAP, their frequency (in paren-
thesis) and their possible mode of multi-drug resistance, 
if any, are listed below [1]–[3]:
1. Pseudomonas (24.4 %): Upregulation of eﬄ  ux pumps, 
decreased expression of outer membrane porin 
 channel, acquisition of plasmid-mediated metallo-
beta-lactamases.
2. S. aureus (20.4 %, of which > 50 % MRSA): Production 
of a penicillin-binding protein (PBP) with reduced 
aﬃ  nity for beta-lactam antibiotics. Encoded by the 
mecA gene.
3. Enterobacteriaceae (14.1 % – includes Klebsiella spp., 
E. coli, Proteus spp., Enterobacter spp., Serratia spp., 
Citro bacter spp.): Plasmid mediated production of 
ESBLs, plasmid-mediated AmpC-type enzyme.
4. Streptococcus species (12.1 %).
5. Hemophilus species (9.8 %).
6. Acinetobacter species (7.9 %): Production of metallo-
enzymes or carbapenemases.
7. Neisseria species (2.6 %).
8. Stenotrophomonas maltophilia (1.7 %).
9. Coagulase-negative staphylococcus (1.4 %).
10. Others (4.7 % – includes Corynebacterium, Moraxella, 
Enterococcus, fungi).
Diagnosis
At the present time, there is no universally accepted, gold 
standard diagnostic criterion for VAP. Several clinical 
methods have been recommended but none have the 
needed sensitivity or speciﬁ city to accurately identify this 
disease [17]. Daily bedside evaluation in conjunction with 
chest radiography can only be suggestive of the presence 
or absence of VAP, but not deﬁ ne it [18]. Clinical 
diagnosis of VAP can still miss about a third of VAPs in 
the ICU compared to autopsy ﬁ ndings and can 
incorrectly diagnose more than half of patients, likely due 
to poor interobserver agreement between clinical criteria 
[8], [18], [19]. Postmortem studies comparing VAP diag-
nosis with clinical criteria showed 69  % sensitivity and 
75 % speciﬁ city, in comparison to autopsy ﬁ ndings [20].
Th e American Th oracic Society (ATS) and the 
Infectious Diseases Society of America (IDSA) guidelines 
recommend obtaining lower respiratory tract samples for 
culture and microbiology [1]. Analysis of these samples 
can be quantitative or qualitative. Th is guideline also 
allows use of tracheal aspirates for their negative 
predictive value (94 % for VAP). Johanson et al. described 
clinical criteria for diagnosis of VAP as follows [21]: Th e 
clinical pulmonary infection score (CPIS) takes into 
account clinical, physiological, microbiological and 
radiographic evidence to allow a numerical value to 
predict the presence or absence of VAP (Table 1) [18], 
[22]. Scores can range between zero and 12 with a score 
of ≥ 6 showing good correlation with the presence of VAP 
[22]. Despite the clinical popularity of the CPIS, debate 
continues regarding its diagnostic validity. One meta-
analysis of 13 studies evaluating the accuracy of CPIS in 
diagnosing VAP reported pooled estimates for sensitivity 
and speciﬁ city for CPIS as 65 % (95 % CI 61–69 %) and 
64  % (95  % CI 60–67  %), respectively [23]. Despite its 
apparent straightforward calculation, the inter-observer 
variability in CPIS calculation remains substantial, 
jeopardizing its routine use in clinical trials [24]. Of all 
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the criteria used to calculate the CPIS, only time-
dependent changes in the PaO2/FiO2 ratio early in VAP 
may provide some predictive power for VAP outcomes in 
clinical trials, namely clinical failure and mortality [25]. 
However, a trial by Singh and colleagues [26] 
demonstrated that the CPIS is an eﬀ ective clinical tool 
for determining whether to stop or continue antibiotics 
for longer than 3 days. In that study, antibiotics were 
discontinued at day 3 for patients who had been random-
ized to receive ciproﬂ oxacin instead of standard of care, if 
their CPIS remained ≤  6. Mortality and length of ICU 
stay did not diﬀ er despite a shorter duration (p = 0.0001) 
and lower cost (p = 0.003) of antimicrobial therapy in the 
experimental as compared with the standard therapy 
arm, and the development of anti microbial resistance 
was lower among patients whose antibiotics were 
discontinued compared to those who received standard 
of care.
1. New or progressive radiographic consolidation or inﬁ l-
trate. In addition, at least 2 of the following:
2. Temperature > 38 °C
3. Leukocytosis (white blood cell count ≥  12,000 cells/
mm3) or leukopenia (white blood cell count <  4,000 
cells/mm3)
4. Presence of purulent secretions
Respiratory samples can be obtained using several 
techniques: Th e ATS/IDSA guidelines note that use of a 
bronchoscopic bacteriologic strategy has been shown to 
reduce 14-day mortality when compared with a clinical 
strategy (16.2 % vs. 25.8 %, p = 0.02) [1]. When samples 
are obtained by BAL techniques (BAL, mini-BAL or 
PSB), the diagnostic threshold is 103 colony forming units 
(cfu)/ml for protected specimen brushing and 104 cfu/ml 
for BAL. In one multicenter study, BAL- and PSB-based 
diagnosis was associated with signiﬁ cantly more 
antibiotic-free days (11.5  ±  9.0 vs. 7.5  ±  7.6, p  <  0.001) 
compared to guideline-based clinical diagnosis alone 
[27]. Th is study also demonstrated short-term mortality 
beneﬁ t in the BAL/PSB group. More recent evidence 
from the Canadian Clinical Trials study of 740 suspected 
VAP patients randomized to BAL or tracheal suctioning 
suggests that (excluding patients known to be colonized/
infected with pseudomonas species or MRSA) similar 
clinical outcomes and overall use of antibiotics is 
observed when either BAL with quantitative culture or 
endotracheal aspiration with non-quantitative culture is 
used for diagnosis [28]. Th is ﬁ nding was conﬁ rmed by a 
Cochrane meta-analysis of 1,367 patients which again 
found no diﬀ erence in mortality in the invasive vs. non-
invasive groups (26.6  % and 24.7  %, respectively), in 
quantitative versus qualitative cultures (relative risk 1.53, 
95 % CI 0.54–4.39) or in antibiotic use [29].
1. Endotracheal aspirate: Easiest to obtain, does not 
require provider involvement.
2. Bronchoalveolar lavage (BAL): Requires bronchoscopic 
guidance.
3. Mini-bronchoalveolar lavage (mini-BAL): Performed 
‘blind’, i. e., without bronchoscopic guidance.
4. Protected specimen brush (PSB): Utilizes a brush at 
the tip of the catheter which is rubbed against the 
bronchial wall.
Once specimens are obtained, the sample is sent for 
Gram stain, culture and sensitivity. Th e Gram stain can 
provide crucial initial clues to the type of organism(s) and 
whether or not the material is purulent (deﬁ ned as ≥ 25 
neutrophils and ≤  10 squamous epithelial cells per low 
power ﬁ eld) [1],[12]. Culture results can be reported as 
semi-quantitative and/or quantitative values. Semi-
quantitative values obtained by endotracheal sampling 
are considered positive when the agar growth is moderate 
Table 1 The clinical pulmonary infection score (CPIS)
Assessed Parameter Result Score
Temperature (°Celsius) 36.5–38.4 °C 0
 38.5–38.9 °C 1
 ≤ 36 or ≥ 39 °C 2
Leukocytes in blood (cells/mm3) 4,000–11,000/mm3 0
 < 4,000 or > 11,000/mm3 1
 ≥ 500 Band cells 2
Tracheal secretions (subjective visual scale) None 0
 Mild/non-purulent 1
 Purulent 2
Radiographic fi ndings (on chest radiography, excluding CHF and ARDS) No infi ltrate 0
 Diff use/patchy infi ltrate 1
 Localized infi ltrate 2
Culture results (endotracheal aspirate) No or mild growth 0
 Moderate or fl orid growth 1
 Moderate or fl orid growth AND pathogen consistent with Gram stain 2
Oxygenation status (defi ned by PaO2:FiO2) > 240 or ARDS 0
 ≤ 240 and absence of ARDS 2
ARDS: acute respiratory distress syndrome; CHF: congestive heart failure
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(+++) or heavy (++++), while quantitative positivity is 
deﬁ ned as ≥  105  cfu/ml. Exact speciation of pathogen 
bacteria and their sensitivity to antibiotics can take a few 
days, but provides invaluable information.
Mechanically ventilated patients in the ICU receive 
frequent chest X-rays and presence of inﬁ ltrate(s) and/or 
consolidation is considered part of diagnostic criteria and 
is widely used. However, there are several clinical 
conditions that have radiographic appearances similar to 
VAP. Th ese conditions are commonly encountered in 
mechanically ventilated patients and include aspiration 
and chemical pneumonitis, atelectasis, congestive heart 
failure, acute respiratory distress syndrome (ARDS), 
pleural eﬀ usion and intra-alveolar hemorrhage to name a 
few. Hence, reliance on chest radiography for the diag-
nosis of VAP is not advisable. Th ere is poor correlation 
between radiographic signs (alveolar inﬁ ltrates, air 
broncho grams) and histopathological diagnosis of pneu-
monia [12]. Th e sensitivity and speciﬁ city of presence of 
inﬁ ltrates on chest X-ray is also not encouraging [12]. On 
the ﬂ ip-side, the negative predictive value of inﬁ ltrates 
may have clinical utility. In a meta-analysis by Klompas, 
the presence or absence of fever, elevated white blood cell 
count, or purulent secretions did not substantively 
predict the probability of infection; however, the absence 
of a new inﬁ ltrate on a plain radiograph lowered the 
likelihood of VAP [18].
VAP must be distinguished from tracheo-bronchitis. 
Clinical features of these diseases can overlap, but only 
VAP will demonstrate the presence of hypoxia and the 
presence of inﬁ ltrate/consolidation on chest radiography 
[12].
Recently, the Centers for Disease Control and 
Prevention (CDC) rolled out new surveillance criteria for 
possible or probable VAP [17]. Th e goals were to capture 
other common complications of ventilator care, to 
improve objectivity of surveillance to allow comparability 
across centers for public reporting, and to minimize 
gaming [30]. Per these new criteria, a period of at least 
2  days of stable or decreasing ventilator settings (daily 
minimum positive end-expiratory pressure [PEEP] or 
fraction of inspired oxygen [FiO2]) followed by consis-
tently higher settings for at least 2 additional calendar 
days is required before a patient can be said to have a 
ventilator-associated condition (VAC). Most VACs are 
attributable to pneumonia, pulmonary edema, atelectasis, 
or ARDS, conditions which all have well researched 
prevention and management strategies [31]. Signs of 
infection/inﬂ ammation (abnormal temperature or white-
cell count and administration of one or more new 
antibiotics for at least 4  days) classify the patient as an 
“infection-related ventilator-associated complication,” or 
IVAC. Presence of purulent secretions (according to 
quantitative Gram staining criteria) and pathogenic 
culture data will label the patient as possible or probable 
VAP. Patients with an IVAC and purulent secretions 
alone or pathogenic cultures alone have “possible pneu-
monia”; those with both purulent secretions and positive 
quantitative or semiquantitative cultures have “probable 
pneumonia”. Probable pneumonia is also deﬁ ned by 
suggestive histopathological features, positive pleural-
ﬂ uid cultures, or diagnostic tests for legionella and 
selected viruses. Chest radiograph ﬁ ndings have been 
excluded in the new criteria because of their subjectivity 
without increased accuracy. Th is is not intended to 
reduce the role of radiography in clinical care. At the 
present time, the new CDC algorithm is for surveillance 
purposes only.
In the United States, VAP has been proposed as an 
indicator of quality of care in public reporting, and its 
prevention is a national patient safety goal. Th e threat of 
non-reimbursement and ﬁ nancial penalties for this 
diagnosis has put pressure on hospitals to minimize VAP 
rates [13]. Th is has resulted in potential artifacts in 
surveil lance with more than 50 % of non-teaching medical 
ICUs in the United States reporting VAP rates close to 
zero [30], [32]. Th ese rates are an order of magnitude 
lower than those in European centers, which utilize 
similar preventive and treatment strategies suggesting 
that reductions in VAP rates may not reﬂ ect improve-
ments in prevention so much as subjective surveillance 
biases. It is anticipated that the new CDC surveillance 
paradigm for ventilator-associated events will help 
achieve a more realistic VAP rate.
Treatment
Selecting the appropriate antibiotic depends on the 
duration of mechanical ventilation. Late onset VAP (> 4 
days) requires broad spectrum antibiotics whereas early 
onset (≤  4  days) can be treated with limited spectrum 
antibiotics [1]. An updated local antibiogram for each 
hospital and each ICU based on local bacteriological 
patterns and susceptibilities is essential to guide 
optimally dosed initial empiric therapy [1]. With any 
empiric antibiotic regimen, de-escalation is the key to 
reduce emergence of resistance [33]. Delays in initiation 
of antibiotic treatment may add to the excess mortality 
risk with VAP [1]. Tables  2 and 3 highlight the recom-
mended treatment regimens for VAP.
Owing to the high rate of resistance to monotherapy 
observed with P. aeruginosa, combination therapy is 
always recommended. Acinetobacter species respond 
best to carbapenems (also active against ESBL positive 
Enterobacteriaceae), colistin, polymyxin B and ampi-
cillin/sulbactam [36], [37]. Although MDR organisms are 
usually associated with late-onset VAP, recent evidence 
suggests that they are increasingly associated with early-
onset VAP as well [37], [38]. Th e role of inhaled 
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antibiotics in the setting of failure of systemic antibiotics 
is unclear [1]. Th e usual duration of treatment for early-
onset VAP is 8 days and longer in the case of late-onset 
VAP or if MDR organisms are suspected or identiﬁ ed 
[39]–[41].
Despite therapy, if no response is observed, it may be 
prudent to reconsider the diagnosis, reassess the 
organism being treated or search for other reasons for 
signs and symptoms. Because of the challenges associated 
with diagnosing VAP, especially early in the course, the 
IDSA/ATS guidelines highlight the importance of re-
assessing patients at 48–72 hours once pertinent data are 
available to determine whether the patient should con-
tinue antibiotic therapy for VAP or whether an alternative 
diagnosis should be pursued. In one study, Swoboda et al. 
[42] found that half of the empiric antibiotic use for VAP 
in two surgical ICUs was prescribed for patients without 
pneumonia.
Prevention
Th ere are multiple recommended measures for preven-
tion of VAP. Th ese measures are summarized in Table 4 
[43]–[46]. Institutions or ICUs may observe a reduction 
in VAP rates by utilizing a ‘VAP-bundle’ approach [44], 
[47] using elements depicted in Table  4. Th e 5-element 
Institute of Healthcare Improvement (IHI) VAP bundle 
[47] includes: Head of bed elevation, oral care with 
chlorhexidine, stress ulcer prophylaxis, deep venous 
thrombosis prophylaxis, and daily sedation assessment 
and spontaneous breathing trials. Each of these elements 
has been shown to reduce the incidence of VAP although 
the quality of evidence supporting the eﬀ ectiveness and 
importance of each intervention has been questioned. 
Even studies using VAP bundles have been criticized as 
failing to demonstrate clinical and cost eﬀ ectiveness [48]. 
A before-after study which systematically implemented a 
VAP prevention bundle using IHI methodology showed a 
Table 2 Comparison of recommended initial empiric therapy for ventilator-associated pneumonia (VAP) according to 
time of onset [1], [34], [41]
Early-onset VAP Late-onset VAP
Second or third generation cephalosporin: e. g., ceftriaxone: 2 g daily;
cefuroxime: 1.5 g every 8 hours;
cefotaxime: 2 g every 8 hours
OR
Fluoroquinolones
e. g., levofl oxacin: 750 mg daily;
moxifl oxacin: 400 mg daily
OR






e. g., cefepime: 1–2 g every 8 hours;
ceftazidime 2 g every 8 hours
OR
Carbepenem
e. g., imipenem + cilastin: 500 mg every 6 hours or 1 g every 8 hours;
meropenem: 1 g every 8 hours
OR
Beta-lactam/beta-lactamase inhibitor








e. g., ciprofl oxacin 400 mg every 8 hours;
levofl oxacin 750 mg daily
PLUS
Coverage for MRSA
e. g., vancomycin: 15 mg/kg every 12 hours
OR
linezolid: 600 mg every 12 hours
Optimal dosage includes adjusting for hepatic and renal failure. Trough levels for vancomycin (15–20 mcg/ml), amikacin (< 5 mcg/ml), gentamicin (< 1 mcg/ml) and 
tobramycin (< 1 mcg/ml) should be measured frequently to avoid untoward systemic side eff ects. All recommended doses are for intravenous infusion. Usual duration 
of therapy is 8 days unless treatment is for multidrug resistant organisms, in which case treatment will be for 14 days.
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signiﬁ cant reduction in VAP rates, antibiotic use and 
MRSA acquisition [43]. Th ere was no reduction, however, 
in duration of mechanical ventilation or ICU admission. 
Th e IHI emphasizes the need for high (95 %) overall com-
pliance rates with VAP bundles although this particular 
study reported overall bundle compliance rates of 70 %. 
Issues with completeness of documentation may under-
estimate compliance, which remains an important feature 
of VAP bundle prevention strategies. Another important 
contribution towards VAP prevention and shortening 
periods of antibiotic exposure was a recent prospective 
study (n  =  129), which concluded that a single-dose of 
Table 3 Recommended therapy for suspected or confi rmed multidrug resistant organisms and fungal VAP [1], [34], [35], 
[41]
Pathogen Treatment
Methicillin-resistant Staphylococcus aureus (MRSA) See Table 2
Pseudomonas aeruginosa Double coverage recommended. See Table 2
Acinetobacter species Carbapenem
e. g., imipenem + cilastin; 1 g every 8 hours;
meropenem 1 g every 8 hours
OR
Beta-Lactam/beta-lactamase inhibitor
e. g., ampicillin + sulbactam: 3 g every 8
hours
OR
Tigecycline: 100 mg loading dose, then 50 mg every 12 hours
Extended-spectrum beta-lactamase (ESBL) positive enterobacteriaceae Carbepenem
e. g., imipenem + cilastin: 1 g every 8 hours;
meropenem: 1 g every 8 hours
Fungi Fluconazole: 800 mg every 12 hours;
caspofungin: 70 mg loading dose, then 50 mg daily;
voriconazole (for aspergillus species): 4 mg/kg every 12 hours
Legionella Macrolides (e. g., azithromycin)
OR
Fluoroquinolones (e. g., levofl oxacin)
Table 4 Suggested measures for prevention of ventilator-associated pneumonia (VAP) [41], [42], [49]
ICU focused measures Institution focused measures
Alcohol-based hand washing policy Surveillance program for pathogen profi ling and creation of “antibiogram”
Early discontinuation of invasive devices Frequent educational programs to reduce unnecessary antibiotic prescription
Reduce reintubation rates Propagate use of non-invasive positive pressure ventilation (NIPPV)
Use of oropharyngeal vs. nasopharyngeal feeding tubes Endotracheal tubes (ETTs) with potential benefi t:
 Polyurethane-cuff ed ETT
 Silver/antibiotic coated ETT
 Aspiration of subglottic secretions (HI-LO ETT)
Semi-recumbent patient positioning (30–45°) Maintain policy for oral decontamination
 Selective digestive decontamination (SDD)
Endotracheal tube cuff  pressure ~ 20 cm H2O Early weaning and extubation
Early tracheostomy Daily sedation holds
Small bowel feeding instead of gastric feeding Preference on using heat-moisture exchangers over heater humidifi ers
Prophylactic probiotics Mechanical removal of the biofi lm (e. g., the mucus shaver)
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antibiotics within 4  h of intubation may be eﬀ ective in 
preventing early onset VAP in a cohort of comatose 
patients [49]. A randomized clinical trial is needed to 
address this question.
Conclusion
VAP occurs frequently and is associated with signiﬁ cant 
morbidity in critically ill patients. Th e primary obstacle 
in diagnosing VAP is the absence of gold standard criteria 
and, therefore, VAP continues to be an inconspicuous 
clinical syndrome. Th ere is enough evidence to indicate 
that VAP is preventable and that hospitals can decrease 
VAP rates, a factor that the new CDC VAP deﬁ nitions are 
poised to demonstrate more objectively. Th e diagnostic 
challenge of VAP has multiple implications for therapy. 
Although a CPIS score > 6 may correlate with VAP, the 
sensitivity, speciﬁ city and inter-rater agreement of this 
criterion alone are not encouraging. Microbiological data 
should be used for tailoring antibiotic therapy and not be 
restricted only to diagnosis. Th e pitfall in using empiric 
antibiotics for suspicion of VAP is the potential for 
antibiotic overuse, emergence of resistance, unnecessary 
adverse eﬀ ects and potential toxicity. Th e major goals of 
VAP management are early, appropriate antibiotics in 
adequate doses followed by de-escalation based on 
microbiological culture results and the clinical response 
of the patient. Antimicrobial stewardship programs 
involving pharmacists, physicians and other healthcare 
providers optimize antibiotic selection, dose, and 
duration to increase eﬃ  cacy in targeting causative 
pathogens and allow the best clinical outcome.
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